trending Market Intelligence /marketintelligence/en/news-insights/trending/K3ClcusXEsXPcnw1y8WT8w2 content esgSubNav
In This List

COSMOS Pharmaceutical fiscal Q2 profit climbs YOY

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


COSMOS Pharmaceutical fiscal Q2 profit climbs YOY

COSMOS Pharmaceutical Corp. said its normalized net income for the fiscal second quarter ended Nov. 30, 2014, was ¥148.42 per share, an increase from ¥144.92 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥2.94 billion, an increase from ¥2.87 billion in the year-earlier period.

The normalized profit margin dropped to 3.0% from 3.3% in the year-earlier period.

Total revenue grew 11.2% year over year to ¥96.47 billion from ¥86.77 billion, and total operating expenses grew 11.6% year over year to ¥92.20 billion from ¥82.59 billion.

Reported net income rose from the prior-year period to ¥2.64 billion, or ¥133.49 per share, from ¥2.55 billion, or ¥128.79 per share.

As of Jan. 14, US$1 was equivalent to ¥116.84.